Bio Banking MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Product & ServiceBy Sample TypeBy End User
Full title & scope — all 5 axes with their segments
Bio Banking Market Size, Share & Industry Analysis, By Type (Population-Based Biobank, Disease-Oriented Biobank, Other), By Application (Research, Therapeutic, Other), By Product & Service (Equipment & Storage Systems, Consumables & Reagents, Services), By Sample Type (Blood Products, Human Tissues, Cell Lines, Others), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Others), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
- 01By TypePopulation-Based Biobank · Disease-Oriented Biobank · Other
- 02By ApplicationResearch · Therapeutic · Other
- 03By Product & ServiceEquipment & Storage Systems · Consumables & Reagents · Services
- 04By Sample TypeBlood Products · Human Tissues · Cell Lines
- 05By End UserAcademic & Research Institutes · Pharmaceutical & Biotechnology Companies · Hospitals & Diagnostic Laboratories
- 06By Region
Market Analysis & Outlook
Biobanking refers to the collection, processing, cataloguing and long-term storage of human biological specimens (blood, tissue, cells, DNA and RNA) together with the clinical and demographic data linked to each sample. It covers the equipment, consumables and services used to keep those specimens viable for years or decades, from ultra-low-temperature freezers and liquid nitrogen storage to sample tracking and shipping. Buyers include hospitals and diagnostic laboratories building clinical sample archives, pharmaceutical and biotechnology companies sourcing specimens for drug discovery and biomarker research, and academic and public health institutions running long-term population or disease cohort studies.
Between 2025 and 2034 the global bio banking market moves from USD 83.3 billion to USD 191.64 billion, compounding at 9.7% a year. Fifteen years are covered in all, taking in USD 58.03 billion in 2020, USD 77.49 billion in 2024, USD 91.38 billion in 2026 and USD 132.33 billion in 2030.
On the type axis, growth rates run from 8.07% for Other up to 11.4% for Disease-Oriented Biobank. Population-Based Biobank carries the volume: USD 43.32 billion and 52% of revenue in 2025, USD 90.07 billion and 47% in 2034. The lines gaining share are Disease-Oriented Biobank. Population-Based Biobank and Other lose share without losing revenue.
By application, Research accounts for 58% of 2025 revenue at USD 48.31 billion, reaching USD 99.65 billion and 52.01% by 2034. Therapeutic grows faster at 12.38% against 8.38%, moving from 33% of revenue to 41% by 2034. This axis divides the same revenue as the type split rather than adding to it, so the two are read together rather than summed.
The regional order runs from North America at 38% of 2025 revenue down to Middle East and Africa at 5%. North America is worth USD 31.65 billion in 2025 and USD 67.07 billion in 2034; Europe, second at 27%, moves from USD 22.49 billion to USD 47.91 billion. Share shifts toward Asia Pacific over the forecast period, which is what makes the regional split worth reading rather than assuming.
Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies rather than a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global bio banking market moves from USD 58.03 billion in 2020 to USD 83.3 billion in 2025 and USD 191.64 billion by 2034, the forecast period compounding at 9.7% a year.
- 52% of 2025 revenue sits in Population-Based Biobank (USD 43.32 billion) and it remains the largest type line in 2034 at USD 90.07 billion and 47%.
- Fastest growth on the type axis belongs to Disease-Oriented Biobank: 11.4% a year, USD 33.32 billion to USD 88.15 billion, and a share moving from 40% to 46%.
- The bull case puts 2034 revenue at USD 214.64 billion and the bear case at USD 172.48 billion, either side of the USD 191.64 billion base case, each with its own stated assumption in the full report.
- The largest region is North America, generating USD 31.65 billion in 2025 (38% of the global total) and USD 67.07 billion by 2034, ahead of Europe at 27%.
- The United States accounts for 85% of North America in the base year, worth USD 26.9 billion in 2025 and reaching USD 57.01 billion by 2034, the worked country example carried through that region's chapters.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.
Market Trends
Revenue Share, By by type
Base year 2025Population-Based Biobank leads with 52.0% of by type segment revenue.
Share of by type segment revenue, most recent base year.
Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 9.7% compounding underneath both.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Composition shifts on the type axis. 11.4% against 8.07%: that gap, between Disease-Oriented Biobank and Other, is the largest on the type axis. Shares follow: 40% to 46% for Disease-Oriented Biobank, 8% to 7% for Other. Revenue rises on both sides; USD 33.32 billion to USD 88.15 billion and USD 6.66 billion to USD 13.41 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Growth concentrates in Asia Pacific. Asia Pacific moves from 24% of revenue in 2025 to 29% in 2034, worth USD 19.99 billion rising to USD 55.58 billion. The offsetting side is North America at 38% moving to 35%, Europe at 27% moving to 25%, Latin America at 6% moving to 6%, Middle East and Africa at 5% moving to 5%, none of which contracts. That makes the regional split worth reading rather than scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
Fifteen years without a discontinuity. Year by year the total runs USD 58.03 billion in 2020, USD 77.49 billion in 2024, USD 83.3 billion in 2025, USD 91.38 billion in 2026, USD 132.33 billion in 2030 and USD 191.64 billion in 2034. The forecast rate of 9.7% sits against 7.5% over the historical period, so the projection extends an observed trend instead of proposing a new one. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.
Market Growth Factors
Disease-Oriented Biobank carries the market's growth rate
Market Drivers
3- 01Disease-Oriented Biobank carries the market's growth rate
11.4% growth in Disease-Oriented Biobank, against 9.7% for the market as a whole, moves it from USD 33.32 billion and 40% of revenue in 2025 to USD 88.15 billion and 46% in 2034. Set against 8.07% at the other end of the axis, this is the line that decides whether the market's 9.7% holds. Exposure to this line, rather than exposure to the market, is what determines a supplier's own rate.
- 02Growth lands where the revenue already is
38% of 2025 revenue (USD 31.65 billion) is generated in North America, reaching USD 67.07 billion by 2034 at an unchanged 35%. Europe adds a further 27% at USD 22.49 billion, reaching USD 47.91 billion. Because both the existing revenue and the revenue added concentrate in these two, regional weighting matters more to a forecast than regional count does.
- 03Fifteen years of unbroken growth underpin the forecast
The historical period compounded at 7.5%; USD 58.03 billion in 2020, USD 77.49 billion in 2024 and USD 83.3 billion in 2025. From there the forecast carries 9.7% through to USD 191.64 billion in 2034. Fifteen years of unbroken growth in the series means the forecast rests on a demonstrated trajectory rather than a projected turnaround, and it is why the 9.7% rate is applied across the whole period rather than ramped through it.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Expansion of precision medicine and biomarker-driven drug development | High | +38 | High | High | High |
| 2 | Growth in cell and gene therapy pipelines requiring banked starting material | High | +24 | Medium | High | High |
| 3 | Rising government and public health investment in population cohort programs | Medium-High | +18 | High | Medium | Medium |
| 4 | Outsourcing of biobanking operations to specialized service providers | Medium | +14 | Low | Medium | Medium |
| 5 | Expansion of biobanking infrastructure across Asia Pacific research institutions | Medium | +12 | Medium | Medium | High |
| 6 | Others | Low | +19.34 | Low | Low | Low |
| Total | +125.34 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | High cost of ultra-low-temperature storage and long-term sample maintenance | Medium-High | −8 | Medium | Medium | Medium |
| 2 | Regulatory and ethical constraints on cross-border sample and data transfer | Medium | −6 | Medium | Medium | Low |
| 3 | Shortage of standardized sample quality and annotation protocols across biobanks | Low | −3 | Low | Low | Low |
| Total | −17 | |||||
Drivers contribute 125.34 Billion and restraints remove 17 Billion, a net 108.34 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 9.7% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Downside case: USD 172.48 billion rather than USD 191.64 billion by 2034
Market Restraints
2- 01Downside case: USD 172.48 billion rather than USD 191.64 billion by 2034
A bear case of USD 172.48 billion in 2034, against USD 191.64 billion in the base case, rests on one stated assumption: bear case assumes tighter research and biopharma R&D budgets delay new cohort program launches and slow the shift from in-house to outsourced biobanking services. Neither case changes the USD 83.3 billion 2025 base.
- 02Population-Based Biobank grows below the market rate
Population-Based Biobank carries 52% of 2025 revenue at USD 43.32 billion but compounds at 8.47% against 9.7% for the market, taking its share to 47% by 2034 even as revenue rises to USD 90.07 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
Bull case assumes faster adoption of outsourced biobanking services and accelerated public funding for population cohort programs, pulling forward specimen storage and processing demand. On that assumption the market reaches USD 214.64 billion by 2034 rather than USD 191.64 billion, from the same USD 83.3 billion in 2025.
- 02Disease-Oriented Biobank share moves from 40% to 46%
Share on the type axis moves toward Disease-Oriented Biobank, from 40% in 2025 to 46% in 2034, on 11.4% growth against the market's 9.7% and revenue rising from USD 33.32 billion to USD 88.15 billion. Taking position there does not require displacing whoever holds Population-Based Biobank, which is the harder and more expensive fight.
Market Challenges
Revenue is concentrated in Population-Based Biobank
Market Challenges
2- 01Revenue is concentrated in Population-Based Biobank
Population-Based Biobank is 52% of 2025 revenue at USD 43.32 billion and still 47% at USD 90.07 billion in 2034. That concentration means the market's own forecast is, to a large extent, a forecast for one type line.
- 02North America is largely the United States
The United States generates USD 26.9 billion of North America's USD 31.65 billion in 2025, 85% of the region, reaching USD 57.01 billion by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.
Segmentation Analysis
5 axesThe market is divided by type and by application, product & service, sample type and end user; five axes in all. They are alternative readings of one revenue pool, not parts that sum to it.
There are three lines on the type axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: one gains it, the rest give it up.
By Type · 3 segments
Disease-Oriented Biobank Outpaces the Axis While Population-Based Biobank Holds the Largest Share
- Largest Population-Based Biobank · 52%
- Fastest Disease-Oriented Biobank · 11.4%
- Moves most Disease-Oriented Biobank · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Population-Based Biobank | $43.32B | 52% | $90.07B | 47%-5 | 8.5% |
| Disease-Oriented Biobank | $33.32B | 40% | $88.15B | 46%+6 | 11.4% |
| Other | $6.66B | 8% | $13.41B | 7%-1 | 8.1% |
Population-Based Biobank leads because population-based cohort programs anchor most long-running national and regional biobanking infrastructure, giving them the largest existing sample inventories. Disease-Oriented Biobank grows fastest because pharmaceutical and biotechnology sponsors increasingly commission cohorts tied to specific conditions to support targeted drug development, favoring purpose-built collections over general population sampling. Population-Based Biobank remains the largest line through 2034, so the axis changes in proportion rather than in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Application · 3 segments
Scale in Research and Growth in Therapeutic Define the Application Axis
- Largest Research · 58%
- Fastest Therapeutic · 12.4%
- Moves most Therapeutic · +8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Research | $48.31B | 58% | $99.65B | 52%-6 | 8.4% |
| Therapeutic | $27.49B | 33% | $78.57B | 41%+8 | 12.4% |
| Other | $7.50B | 9% | $13.41B | 7%-2 | 6.7% |
Research leads because most biobank specimens are still collected and stored to support academic and translational research programs rather than direct treatment use. Therapeutic grows fastest because cell and gene therapy developers increasingly draw on banked biospecimens to source starting material and validate manufacturing processes, pulling biobanking activity closer to the clinic. The order does not change: Research is still largest in 2034, and what moves is how much it holds.
By Product & Service · 3 segments
Equipment & Storage Systems Held the Dominant Share of the Product & service Segment in 2025
- Largest Equipment & Storage Systems · 42%
- Fastest Services · 11.9%
- Moves most Services · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Equipment & Storage Systems | $34.99B | 42% | $70.91B | 37%-5 | 8.2% |
| Consumables & Reagents | $22.49B | 27% | $49.83B | 26%-1 | 9.2% |
| Services | $25.82B | 31% | $70.91B | 37%+6 | 11.9% |
Equipment and storage systems lead because reliable ultra-low-temperature freezers, liquid nitrogen systems and monitoring infrastructure are the upfront cost every biobank must fund before any sample handling can begin. Services grow fastest because institutions increasingly outsource sample processing, storage and logistics to specialized providers rather than building and staffing that capability internally, shifting spend from capital purchases to ongoing service contracts. Equipment & Storage Systems remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Sample Type · 4 segments
Scale in Blood Products and Growth in Cell Lines Define the Sample type Axis
- Largest Blood Products · 45%
- Fastest Cell Lines · 13.3%
- Moves most Cell Lines · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Blood Products | $37.49B | 45% | $78.57B | 41%-4 | 8.6% |
| Human Tissues | $23.32B | 28% | $49.83B | 26%-2 | 8.8% |
| Cell Lines | $15B | 18% | $46B | 24%+6 | 13.3% |
| Others | $7.50B | 9% | $17.25B | 9% | 9.7% |
Blood products lead because blood draws remain the simplest, least invasive specimen to collect at scale across hospital and population-cohort settings. Cell lines grow fastest because biopharmaceutical developers increasingly need immortalized and patient-derived lines to support cell therapy and drug screening programs, a use case blood and tissue archives alone cannot serve. The order does not change: Blood Products is still largest in 2034, and what moves is how much it holds.
By End User · 4 segments
Scale in Academic & Research Institutes and Growth in Pharmaceutical & Biotechnology Companies Define the End user Axis
- Largest Academic & Research Institutes · 40%
- Fastest Pharmaceutical & Biotechnology Companies · 12.1%
- Moves most Pharmaceutical & Biotechnology Companies · +7 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Academic & Research Institutes | $33.32B | 40% | $67.07B | 35%-5 | 8.1% |
| Pharmaceutical & Biotechnology Companies | $26.66B | 32% | $74.74B | 39%+7 | 12.1% |
| Hospitals & Diagnostic Laboratories | $16.66B | 20% | $36.41B | 19%-1 | 9.1% |
| Others | $6.66B | 8% | $13.41B | 7%-1 | 8.1% |
Academic and research institutes lead because most established biobanks originated inside universities and public research bodies building long-term population or disease cohorts. Pharmaceutical and biotechnology companies grow fastest because drug developers increasingly license or commission banked specimens to support biomarker discovery and clinical trial patient stratification, pulling demand toward commercial sponsors. Leadership changes hands: Pharmaceutical & Biotechnology Companies is the largest line by 2034, not Academic & Research Institutes.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3 points of share move elsewhere by 2034, while revenue still grows 2.1×.
- Rank 1 of 5
- 2025 share 38%
- By 2034 35%
- Revenue $31.65B → $67.07B
In North America, 38% of global revenue puts 2025 at USD 31.65 billion with USD 67.07 billion projected for 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
35% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the type split tracks the global one; 52% of 2025 revenue in Population-Based Biobank, fastest growth of 11.4% in Disease-Oriented Biobank. Per-axis and per-country detail for North America sits in the full report.
United States
Sets the pace for North America at 85% of it, growing 2.1×.
- In region 1 of 2
- Of region 85%
- Of global 32.3%
- Revenue $26.90B → $57.01B
The United States is the largest market within North America, generating USD 26.9 billion in 2025 and projected to reach USD 57.01 billion by 2034. Carrying 85% of the region in the base year, it sets North America's direction rather than contributing to it. Against regional totals of USD 31.65 billion in 2025 and USD 67.07 billion in 2034, it is the country the full report breaks out in detail.
the United States buys along the same lines as the market globally; Population-Based Biobank first at 52% of 2025 revenue and 47% in 2034, Disease-Oriented Biobank fastest at 11.4% on a share moving from 40% to 46%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The United States carries its own type breakdown in the full report.
Biobanking in the United States falls primarily under the Food and Drug Administration's oversight of human cells, tissues, and cellular and tissue-based products, which requires establishments that recover, process, store, or distribute such material to register with the agency, screen and test donors, and follow current good tissue practice requirements covering facility controls, traceability, and labelling. Laboratories performing testing on stored specimens must additionally meet Clinical Laboratory Improvement Amendments requirements, and many biobanks pursue voluntary accreditation from bodies such as the College of American Pathologists or the American Association of Tissue Banks to demonstrate conformity with recognized quality and chain-of-custody standards. Handling of associated health information is further constrained by federal privacy law governing identifiable patient data.
Competition in the United States runs between the suppliers this study tracks: BioIVT & Elevating Science, Geneticist Inc, Firalis S.A, AMS Biotechnology Ltd. (AMSBIO LLC), US Biolab Corporation Inc, ProteoGenex Inc., Cureline Inc., Bay Biosciences LLC, CTI Biotech, Boca Biolistics, Discovery Life Sciences, iSpecimen Inc., Indivumed GmbH, Tissue Solutions Ltd and Others. Population-Based Biobank, at 52% of 2025 revenue, is where the volume sits, and Disease-Oriented Biobank, growing at 11.4%, is where position changes hands over the forecast period. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.
Canada
2nd-largest in North America, growing 2.1×.
- In region 2 of 2
- Of region 15%
- Of global 5.7%
- Revenue $4.75B → $10.06B
5.7% of global revenue is generated in Canada; USD 4.75 billion in 2025, reaching USD 10.06 billion in 2034, and 15% of North America.
Europe Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 2.1×.
- Rank 2 of 5
- 2025 share 27%
- By 2034 25%
- Revenue $22.49B → $47.91B
USD 22.49 billion of 2025 revenue is generated in Europe, 27% of the global bio banking market on the way to USD 47.91 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share stands at 25%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.
Population-Based Biobank leads here as it does globally, at 52% of 2025 revenue, and Disease-Oriented Biobank again grows fastest at 11.4%. The full report breaks Europe out along every axis and by country.
United Kingdom
The largest market in Europe, growing 2.1×.
- In region 1 of 3
- Of region 30%
- Of global 8.1%
- Revenue $6.75B → $14.37B
30% of Europe's base-year revenue comes from the United Kingdom; USD 6.75 billion, rising to USD 14.37 billion by 2034. It accounts for 30% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 22.49 billion in 2025 and USD 47.91 billion in 2034, it is the country the full report breaks out in detail.
the United Kingdom buys along the same lines as the market globally; Population-Based Biobank first at 52% of 2025 revenue and 47% in 2034, Disease-Oriented Biobank fastest at 11.4% on a share moving from 40% to 46%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. The United Kingdom carries its own type breakdown in the full report.
In the United Kingdom, storage of human tissue and cells for research, treatment, or future use is licensed and inspected by the Human Tissue Authority under the Human Tissue Act, which sets consent, traceability, and quality standards that biobanks must satisfy to obtain and retain a storage licence. Where samples are processed for therapeutic application rather than research alone, the Medicines and Healthcare products Regulatory Agency's requirements for tissues and cells intended for human use also apply, covering donor selection, testing, and traceability from donation through to use or disposal. Biobanks typically operate under a code of practice addressing governance, ethical approval, and public transparency about how stored material and associated data may be used.
In the United Kingdom the field is BioIVT & Elevating Science, Geneticist Inc, Firalis S.A, AMS Biotechnology Ltd. (AMSBIO LLC), US Biolab Corporation Inc, ProteoGenex Inc., Cureline Inc., Bay Biosciences LLC, CTI Biotech, Boca Biolistics, Discovery Life Sciences, iSpecimen Inc., Indivumed GmbH, Tissue Solutions Ltd and Others. Volume sits in Population-Based Biobank at 52% of 2025 revenue; movement sits in Disease-Oriented Biobank at 11.4% growth.
Germany
2nd-largest in Europe, growing 2.1×.
- In region 2 of 3
- Of region 27%
- Of global 7.3%
- Revenue $6.07B → $12.94B
Germany is sized at USD 6.07 billion in 2025, rising to USD 12.94 billion by 2034; 7.29% of global revenue and 27% of Europe. It is reported separately from the United Kingdom across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 2.1×.
- In region 3 of 3
- Of region 18%
- Of global 4.9%
- Revenue $4.05B → $8.62B
France is sized at USD 4.05 billion in 2025, rising to USD 8.62 billion by 2034; 4.86% of global revenue and 18% of Europe. It is reported separately from the United Kingdom across every segmentation axis in the full report.
Asia Pacific Market Analysis
The 3rd-largest region covered, and the one gaining the most — it picks up 5 points of share by 2034, while revenue still grows 2.8×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 29%
- Revenue $19.99B → $55.58B
Asia Pacific holds 24% of the global bio banking market in 2025, worth USD 19.99 billion rising to USD 55.58 billion in 2034. That makes it the third-largest region covered, in 2025 and again in 2034.
Its share rises to 29% over the forecast period, at a pace above the 9.7% global rate, which is what makes this region worth reading separately rather than scaling from the total.
The type mix reported at global level applies here, with Population-Based Biobank the largest line at 52% of 2025 revenue and Disease-Oriented Biobank the fastest-growing at 11.4%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.8×.
- In region 1 of 3
- Of region 35%
- Of global 8.4%
- Revenue $7B → $19.45B
35% of Asia Pacific's base-year revenue comes from China; USD 7 billion, rising to USD 19.45 billion by 2034. At 35% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 19.99 billion in 2025 and USD 55.58 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
China buys along the same lines as the market globally; Population-Based Biobank first at 52% of 2025 revenue and 47% in 2034, Disease-Oriented Biobank fastest at 11.4% on a share moving from 40% to 46%. Its 35% weight in Asia Pacific means those movements carry straight into the regional totals. China carries its own type breakdown in the full report.
Biobanking activity in China sits at the intersection of medical product regulation and human genetic resource control. The National Medical Products Administration oversees biological products and related manufacturing and quality standards, while the collection, storage, export, and international collaborative use of human genetic material is separately governed by China's human genetic resources management framework, administered by the national office responsible for approving collection and cross-border transfer of such resources. Operators must obtain the relevant administrative approval before collecting or exporting samples, maintain records demonstrating lawful consent and traceability, and comply with biosafety and data-security requirements that apply to genetic and health-related information alongside the physical material itself.
Competition in China runs between the suppliers this study tracks: BioIVT & Elevating Science, Geneticist Inc, Firalis S.A, AMS Biotechnology Ltd. (AMSBIO LLC), US Biolab Corporation Inc, ProteoGenex Inc., Cureline Inc., Bay Biosciences LLC, CTI Biotech, Boca Biolistics, Discovery Life Sciences, iSpecimen Inc., Indivumed GmbH, Tissue Solutions Ltd and Others. Population-Based Biobank, at 52% of 2025 revenue, is where the volume sits, and Disease-Oriented Biobank, growing at 11.4%, is where position changes hands over the forecast period.
Japan
2nd-largest in Asia Pacific, growing 2.8×.
- In region 2 of 3
- Of region 25%
- Of global 6%
- Revenue $5B → $13.90B
Within Asia Pacific, Japan accounts for 25% of regional revenue and 6% of the global total, worth USD 5 billion in 2025 and USD 13.9 billion by 2034.
India
3rd-largest in Asia Pacific, growing 2.8×.
- In region 3 of 3
- Of region 15%
- Of global 3.6%
- Revenue $3B → $8.34B
3.6% of global revenue is generated in India; USD 3 billion in 2025, reaching USD 8.34 billion in 2034, and 15% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.3×.
- Rank 4 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $5B → $11.50B
6% of the global bio banking market sits in Latin America in 2025, worth USD 5 billion with USD 11.5 billion projected for 2034. Among the five regions it ranks fourth by revenue in both years.
6% of global revenue sits here in 2034, below the 2025 level, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.
Within the region the type split tracks the global one; 52% of 2025 revenue in Population-Based Biobank, fastest growth of 11.4% in Disease-Oriented Biobank. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.
Brazil
The largest market in Latin America, growing 2.3×.
- In region 1 of 2
- Of region 45%
- Of global 2.7%
- Revenue $2.25B → $5.18B
USD 2.25 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 5.18 billion by 2034. 45% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 5 billion in 2025 and USD 11.5 billion in 2034, it is the country the full report breaks out in detail.
Demand in Brazil follows the type mix reported at global level: Population-Based Biobank is the largest line at 52% of 2025 revenue, moving to 47% by 2034, while Disease-Oriented Biobank grows fastest at 11.4% and takes its share from 40% to 46%. Since 45% of Latin America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The full report reports Brazil by type separately.
In Brazil, biobanks and biorepositories are regulated by the National Health Surveillance Agency, whose resolutions establish operating standards covering facility licensing, quality management, traceability, and the storage conditions required for human biological material held for research or therapeutic purposes. Research uses additionally require review and approval by the National Research Ethics Commission and its affiliated ethics committees, which assess consent arrangements and the permitted future use of stored samples. Suppliers are expected to demonstrate documented chain-of-custody from collection through storage and eventual use or disposal, and to align internal quality practices with recognized biobanking standards even though no single certification is mandatory nationwide.
BioIVT & Elevating Science, Geneticist Inc, Firalis S.A, AMS Biotechnology Ltd. (AMSBIO LLC), US Biolab Corporation Inc, ProteoGenex Inc., Cureline Inc., Bay Biosciences LLC, CTI Biotech, Boca Biolistics, Discovery Life Sciences, iSpecimen Inc., Indivumed GmbH, Tissue Solutions Ltd and Others are the suppliers covered in Brazil. The commercially relevant division is 52% of 2025 revenue in Population-Based Biobank, where the volume is, against 11.4% growth in Disease-Oriented Biobank, where share moves.
Mexico
2nd-largest in Latin America, growing 2.3×.
- In region 2 of 2
- Of region 30%
- Of global 1.8%
- Revenue $1.50B → $3.45B
1.8% of global revenue is generated in Mexico; USD 1.5 billion in 2025, reaching USD 3.45 billion in 2034, and 30% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.3×.
- Rank 5 of 5
- 2025 share 5%
- By 2034 5%
- Revenue $4.17B → $9.58B
In Middle East and Africa, 5% of global revenue puts 2025 at USD 4.17 billion and reaches USD 9.58 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.
5% of global revenue sits here in 2034, below the 2025 level, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
The type mix reported at global level applies here, with Population-Based Biobank the largest line at 52% of 2025 revenue and Disease-Oriented Biobank the fastest-growing at 11.4%. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.3×.
- In region 1 of 2
- Of region 35%
- Of global 1.8%
- Revenue $1.46B → $3.35B
USD 1.46 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 3.35 billion by 2034. At 35% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 4.17 billion in 2025 and USD 9.58 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Saudi Arabia buys along the same lines as the market globally; Population-Based Biobank first at 52% of 2025 revenue and 47% in 2034, Disease-Oriented Biobank fastest at 11.4% on a share moving from 40% to 46%. Its 35% weight in Middle East and Africa means those movements carry straight into the regional totals. Saudi Arabia carries its own type breakdown in the full report.
Biobanking in Saudi Arabia is overseen chiefly by the Saudi Food and Drug Authority, which sets licensing and quality requirements for facilities handling human tissue and biological samples, alongside ethical review by the National Committee of Bioethics, which governs consent, permitted research use, and cross-border sample transfer for genetic and biological material. Operators are generally expected to register facilities, document donor consent and sample provenance, and follow biosafety and quality-management practices consistent with recognized international biobanking standards, since the country has limited biobank-specific legislation of its own and instead applies these general health-product and research-ethics frameworks to the activity. Labelling and traceability through storage remain a baseline expectation across handled material.
Competition in Saudi Arabia runs between the suppliers this study tracks: BioIVT & Elevating Science, Geneticist Inc, Firalis S.A, AMS Biotechnology Ltd. (AMSBIO LLC), US Biolab Corporation Inc, ProteoGenex Inc., Cureline Inc., Bay Biosciences LLC, CTI Biotech, Boca Biolistics, Discovery Life Sciences, iSpecimen Inc., Indivumed GmbH, Tissue Solutions Ltd and Others. Two different problems sit on the same axis: holding Population-Based Biobank at 52% of 2025 revenue, and taking Disease-Oriented Biobank while it grows at 11.4%.
South Africa
2nd-largest in Middle East and Africa, growing 2.3×.
- In region 2 of 2
- Of region 25%
- Of global 1.3%
- Revenue $1.04B → $2.40B
South Africa is sized at USD 1.04 billion in 2025, rising to USD 2.4 billion by 2034; 1.25% of global revenue and 25% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, product & service, sample type, end user, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Population-Based Biobank Volume and Disease-Oriented Biobank Momentum
The study covers the following suppliers: BioIVT & Elevating Science, Geneticist Inc, Firalis S.A, AMS Biotechnology Ltd. (AMSBIO LLC), US Biolab Corporation Inc, ProteoGenex Inc., Cureline Inc., Bay Biosciences LLC, CTI Biotech, Boca Biolistics, Discovery Life Sciences, iSpecimen Inc., Indivumed GmbH, Tissue Solutions Ltd and Others.
The competitive line that matters is the type one, not the geographic one. Population-Based Biobank is 52% of 2025 revenue at USD 43.32 billion and still 47% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Disease-Oriented Biobank, compounding at 11.4% against 8.07% for Other, is where share changes hands over the forecast period. A supplier positioned in one is not automatically positioned in the other, which is what keeps a field of this size viable in a market of USD 83.3 billion.
What separates suppliers in biobanking is less about price and more about trust in sample integrity. The largest players hold advantages in cold-chain reliability (redundant power, continuous temperature monitoring and disaster recovery) plus track records with institutional review boards and data protection regulators across multiple jurisdictions, which shortens the qualification process for new sponsor relationships. Multi-site collection networks and established chain-of-custody documentation matter for large cohort programs. Smaller and regional providers instead compete on specialization in a narrow sample type or disease area, faster turnaround for local hospital systems, and lower-cost storage for programs that do not require global reach.
The regional picture sets the entry cost: 38% of revenue is in North America and 27% in Europe, so a credible global position requires both, while Middle East and Africa at 5% can be served opportunistically.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Bio Banking Companies Profiled
15 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- BioIVT & Elevating Science(United States)
- Geneticist Inc(United States)
- Firalis S.A(France)
- AMS Biotechnology Ltd. (AMSBIO LLC)(United Kingdom)
- US Biolab Corporation Inc(United States)
- ProteoGenex Inc.(United States)
- Cureline Inc.(United States)
- Bay Biosciences LLC(United States)
- CTI Biotech(France)
- Boca Biolistics(United States)
- Discovery Life Sciences(United States)
- iSpecimen Inc.(United States)
- Indivumed GmbH(Germany)
- Tissue Solutions Ltd(United Kingdom)
- Others
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Application, Product & Service, Sample Type, End User), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 15 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Bio Banking Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Bio Banking Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Bio Banking Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Bio Banking Market Overview, By Product & Service, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Bio Banking Market Overview, By Sample Type, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Bio Banking Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Bio Banking Market Size — Segment Comparison
Chapter 22.Global Bio Banking Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Bio Banking Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Bio Banking Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Bio Banking Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Bio Banking Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Bio Banking Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
3- 01Population-Based Biobank
- 02Disease-Oriented Biobank
- 03Other
By Application
3- 01Research
- 02Therapeutic
- 03Other
By Product & Service
3- 01Equipment & Storage Systems
- 02Consumables & Reagents
- 03Services
By Sample Type
4- 01Blood Products
- 02Human Tissues
- 03Cell Lines
- 04Others
By End User
4- 01Academic & Research Institutes
- 02Pharmaceutical & Biotechnology Companies
- 03Hospitals & Diagnostic Laboratories
- 04Others
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
Market sizing combined bottom-up and top-down analysis. The bottom-up estimate builds from the installed base of biobanking storage units (ultra-low-temperature freezers, liquid nitrogen tanks and automated storage systems) deployed across hospitals, academic biobanks and contract biobanking service providers, multiplied by average per-unit spend on equipment, consumables and maintenance contracts. The top-down estimate starts from disclosed and estimated procurement budgets at pharmaceutical, biotechnology and academic research institutions allocated to specimen collection, storage and biobanking services, cross-checked against publicly reported biobank program budgets and grant funding for population cohort studies. The two approaches were reconciled at the regional level, with variances resolved by weighting toward the estimate with stronger underlying disclosure for that region.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary interviews targeted procurement and laboratory operations leads at hospital and academic biobanks, biospecimen sourcing managers at pharmaceutical and biotechnology companies, business development contacts at contract biobanking service providers, and regulatory affairs staff familiar with cross-border sample transfer requirements. Sampling emphasized North America and Europe, where established biobank networks and disclosed procurement practices provide the clearest reference points, supplemented by discussions with research institute administrators in Asia Pacific to capture the region's expanding public and private biobank infrastructure. Findings were weighted toward respondents with direct budget or purchasing authority over storage equipment, consumables or outsourced biobanking services rather than end users of banked specimens.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Bio Banking projected to reach?
USD 191.64 Billion by 2034, CAGR 9.7%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 38% of global revenue through 2034.
05Which segment leads the market?
Population-Based Biobank is the largest line by type, at 52% of revenue in 2025.
06Who are the key companies profiled?
BioIVT & Elevating Science, Geneticist Inc, Firalis S.A, AMS Biotechnology Ltd. (AMSBIO LLC), US Biolab Corporation Inc, ProteoGenex Inc., Cureline Inc., Bay Biosciences LLC, CTI Biotech, Boca Biolistics, Discovery Life Sciences, iSpecimen Inc., Indivumed GmbH, Tissue Solutions Ltd, Others. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.